Resmed Inc. Aktie
219,40 €
Deine Einschätzung
Resmed Inc. Aktie
Was spricht für und gegen Resmed Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Resmed Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Resmed Inc. | 0,37 % | -2,36 % | 9,37 % | 64,47 % | 39,97 % | -9,45 % | 81,53 % |
Thermo Fisher Scientific Inc. | -1,17 % | -0,27 % | -0,42 % | 16,53 % | 14,11 % | 9,34 % | 104,50 % |
QuidelOrtho Corp. | 1,45 % | 2,45 % | 6,09 % | -40,61 % | -38,37 % | -67,90 % | -27,35 % |
Waters Corp. | 1,17 % | 1,85 % | -1,21 % | 16,62 % | 0,40 % | -10,30 % | 46,79 % |
Kommentare
News
Why ResMed Stock Tumbled by 5% Today
Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is